MS

There can be absolutely no excuse for anyone experiencing the first signs and symptoms of neurological conditions like MS having to wait a long time to see an appropriate specialist, such as a neurologist. Delays in seeing specialists is a complaint often heard from patients in various countries, and it…

Waking up in the morning and facing the world brings a sense of wonder. Not in the sense of awe, just in wondering how MS will affect me today. Is it a good day or a bad day? What will it bring? Like most people,…

A review article published in the British Journal of Pharmacology assesses antioxidant approaches for treating neurodegenerative disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The review, “Microglia antioxidant systems and redox signalling,” notes that certain compounds associated with oxidative stress appear to be promising…

Remyelination at the moment is the buzzword to beat all buzzwords in the world of research into, and treatment for, the vicious disease that is multiple sclerosis. Now, as you are reading this, you must have some knowledge of MS and are sure to know about the link between the…

Being lonely can be very difficult to define as it is not only the popularly assumed situation of being alone. You can be lonely in a room full of people if you don’t know anyone well enough to speak to them; conversely, you can be happy when alone, in your…

A Satellite Symposia entitled “Discovering a new world in MS” supported by Teva Neuroscience was held yesterday, October 8, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently taking place in Barcelona, Spain, October 7 – 10, 2015. Prof. David Brassat…

Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D level–related factors,” appeared October 7, 2015 in the journal Neurology.

Three “Hot Topic Sessions” on multiple sclerosis will take place this afternoon (17:00 – 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 – 10. The first session is entitled…

Genzyme recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that Aubagio® (teriflunomide) was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing multiple sclerosis (RMS). Brain volume loss (BVL)…

Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRA® (dalfampridine) Extended Release Tablets (10 mg)  at this year’s 31st Congress of the European Committee for Treatment and Research in…

A number of studies have previously suggested a negative effect of high cholesterol levels on the development of brain lesions in patients with multiple sclerosis (MS), however, little is known about the effect of HDL (high-density lipoprotein) cholesterol, or “good” cholesterol, on MS. A team of scientists from the University…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) begins today, October 7, 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress will focus heavily on Teaching Courses in several topics related to multiple sclerosis (MS)…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress is heavily focused on Teaching Courses in several topics related to multiple…

The 31st meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (#ECTRIMS2015) is being held this week from October 7 to 10 in Barcelona, Spain. The conference was last held in the Catalonian capital in 1992. Multiple Sclerosis News Today…

Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…

A new study recently published in the journal BMC Neurology revealed that natalizumab (TYSABRI) is a safe and effective medication for pediatric cases of multiple sclerosis (MS). The study is entitled “Natalizumab in the pediatric MS population: results of the Italian registry” and was…

Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase III clinical trial (ORATORIO) assessing its investigational therapy ocrelizumab as a treatment for patients with primary progressive multiple sclerosis (PPMS). Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder that results from…

Medical Need Europe, a privately held pharmaceutical company headquartered in Sweden and focused on registration, distribution, marketing and sale of orphan drugs and niche speciality pharmaceuticals for treatment of rare diseases, has appointed London, U.K. based Durbin PLC, a leading global supplier and distributor of pharmaceuticals, to manage…

Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important implications for multiple sclerosis (MS) treatment. The studies are entitled “JC polyomavirus mutants escape antibody-mediated neutralization” and “Broadly neutralizing human…

A study led by researchers from the University of Buffalo recently reported the development of a new method to study brain cell interaction more precisely. The study, published in the journal Nature Communications and entitled “Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral…

An international research team recently reported that the web-based MSdialog app is being adopted by both multiple sclerosis (MS) patients and healthcare providers. The study is entitled “Patient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosis” and was published in the journal…

Multiple sclerosis (MS) is a condition which damages parts of neurons resulting in inefficient communication within the nervous system. It is believed that autoimmune disorders and environmental factors, such as infections, can cause MS disease development. There is currently no cure for MS, although the disease can be managed by medications…

A new study recently published in the journal PLOS One revealed that multiple sclerosis (MS) patients have a microbial imbalance (dysbiosis) in their gut microbiota that is most likely linked to the disease pathogenesis. The study is entitled “Dysbiosis in the Gut Microbiota of…

Biogen recently announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, to exclusively license the company’s experimental product MT-1303. The product is a late stage experimental oral compound developed as a therapy for several autoimmune conditions. MT-1303 is a sphingosine 1-phosphate (S1P)…

A recently published study in the journal Multiple Sclerosis and Related Disorders found notably higher mortality and comorbidity rates among patients suffering from multiple sclerosis (MS) compared to those without the disease. While past studies have reported similar observations, much remains to be understood about MS patients’ risk…

A new study entitled “Effect of Smoking Cessation on Multiple Sclerosis Prognosis” recently revealed that smoking by patients with multiple sclerosis (MS) post diagnosis accelerates their disease progression course. The study was published in the journal JAMA Neurology and was led by researchers at the…

An international team led by researchers at McGill University in Canada recently published in the journal PLOS Medicine data supporting a link between low vitamin D levels and the risk of multiple sclerosis (MS). The study is entitled “Vitamin D and Risk of Multiple…

The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation (MSSRF) have announced the awarding of a $3.2 million grant in support of the Canadian Pediatric Demyelinating Disease Network. Canada has the highest rate of multiple sclerosis (MS) in the world, and is one of the…

A new study published in the journal Statistical Methods in Medical Research revealed a new method to determine the disease course in multiple sclerosis (MS) patients. The study is entitled “Joint assessment of dependent discrete disease state processes” and was conducted by researchers at…

Most people know that eating too much salt is bad for your health, but a new study suggests that it could also increase the risk for multiple sclerosis (MS). The work appeared in the August 2015 issue of The FASEB Journal, the journal of the Federation of…